Amarin Corporation plc (NASDAQ:AMRN)
AMRN, previously announced that its New Drug Application (NDA) for AMR101 has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA��s determination that the application is sufficiently complete to permit a substantive review.
Amarin’s NDA, submitted to FDA on September 26, 2011, seeks approval to market and sell AMR101 in the United States for the indication studied in the MARINE trial–the treatment of patients with very high triglycerides (>=500mg/dL). The NDA for AMR101 is supported by data from both Phase 3 AMR101 clinical trials, MARINE and ANCHOR, in which trials AMR101 achieved all of the primary endpoints and was well tolerated with a safety profile comparable to placebo.
AMRN is a late-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company��s lead product candidate is AMR101 (icosapent ethyl). Amarin reported positive, statistically significant top-line results for both of its two pivotal Phase 3 clinical trials, the MARINE trial (investigation of AMR101 as a treatment for patients with very high triglycerides [>=500 mg/dL]), as reported in November 2010, and the ANCHOR trial (investigation of AMR101 for the treatment of patients on statin therapy with high triglycerides [>=200 and <500mg/dL] with mixed dyslipidemia), as reported in April 2011. Both the MARINE and ANCHOR trials were conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. In September 2011, Amarin submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of AMR101 for treatment of the patient population studied in the MARINE trial! . Amarin plans to separately seek approval for the population studied in the ANCHOR trial after its REDUCE-IT cardiovascular outcomes trial is substantially underway. In August 2011, an SPA agreement with the FDA was reached for the REDUCE-IT cardiovascular outcomes study. The Company seeks to have this study substantially underway before the end of 2012.
For more inormation about AMRN please visit http://www.amarincorp.com
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced that company management will participate in the 23rd Annual Piper Jaffray Healthcare Conference on November 29 at 2:30 pm ET in New York City. Company management will provide a brief overview of the company followed by a question and answer period with investors.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA).
Crown Equity Holdings, Inc. (CRWE)
Crown Equity Holdings Inc., together with its digital network of Websites, offers media advertising, branding and marketing services as a worldwide online multi-media publisher. The company focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Its advertising services cover and connect a range of marketing specialties, as well as providing search engine optimization for clients interested in online media awareness.
Crown Equity Holdings Inc. (CRWE.OB) announced that its subsidiary Crown Tele Services Inc. has entered into a letter of intent with AVIX Technologies, Inc., which sets forth terms by which AVIX Technologies, Inc. will acquire an exclusive licensing agreement for Canada and a non-exclusive global licensing agreement in the hospitality, foodservice and tourism industries for telecommunications including VoIP (Voice Over Internet Protocol) telecom techn! ology sy stems for residential and commercial services, calling card and cellular phone applications.
Crown Tele Services Inc. is a provider of affordable, world class (VoIP) communications solutions and is a wholly owned subsidiary of Crown Equity Holdings Inc.
Crown Equity Holdings Inc. offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Its advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
VoIP systems demonstrate cost-effectiveness much better than traditional voice networks. As VoIP technology evolves, the cost ratio to benefit is bound to increase. Some of the advantages of VoIP technology are as follows:
New Integrated applications: VoIP is digital and hence it may offer features and services that is not possible with a traditional phone.
Cost Reduction: No call tolls even when you use an Internet connection. Use the service to call anyone without having to pay anything for it as long as you have an Internet connection. You can also talk with many people simultaneously at the same time without having to shell extra bucks which imply low-cost conferencing.
Single unified network: As voice is converted into data, the packets are sent over data network and hence there is no need of a voice network at all.
Open standards: VoIP actually supports open architecture and is flexible enough to be integrated with backend systems.
For more information please visit official website of CRWE: www.crownequityholdings.com
York Water Co. (Nasdaq:YORW) announced that the Board of Directors at their November 21st meeting increased the quarterly dividend from $0.131 per share to $0.1336 per s! hare, an increase of 2.0%. The annualized dividend yield based on yesterday’s stock market closing is about 3.2%. The dividend is payable January 17, 2012 to shareholders as of record date December 31, 2011.
The York Water Company engages in impounding, purifying, and distributing drinking water in Pennsylvania.
Healthstream Inc. (Nasdaq:HSTM) announced that it has closed its previously announced public offering of 3,250,000 shares of its common stock, consisting of 3,100,000 shares sold by the Company and 150,000 shares sold by certain selling shareholders at a price of $16.25 per share.
HealthStream, Inc. provides Internet-based learning and research solutions in the United States. The company operates in two segments, HealthStream Learning and HealthStream Research.
No comments:
Post a Comment